Mathematical modelling of immune persistence and relapse pathways in CAR T-cell therapy for B-ALL

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of B-cell acute lymphoblastic leukaemia (B-ALL). Despite high initial response rates, a substantial fraction of patients relapse, often due to loss of CAR T-cell persistence, antigen escape, or immune-privileged sites that shield tumour cells. Prolonged CAR T-cell persistence is clinically associated with durable remission, but why it is required remains poorly understood. To address this, we develop and analyse the BEAM (Blast, Effector, Activated, Memory) model of CAR T-cell dynamics in B-ALL. BEAM extends predator--prey models with three CAR T-cell states (memory, activated, effector) coupled to a logistic growth equation for the blasts, calibrated against the FELIX trial of obecabtagene autoleucel in adult B-ALL. We find that both memory and effector persistence prevent relapse, but for distinct reasons: memory persistence sustains surveillance against low-burden or slowly proliferating residual disease, while effector persistence clears isolated blasts emerging from immune-privileged sites. The model further predicts a trade-off between immediate cytotoxicity and durable surveillance, and identifies initial tumour burden as a key modifiable factor for reducing antigen-negative relapse. Together, these results offer a framework for designing more durable, individually tailored CAR T-cell therapies.